At Deep Biotech Solutions, we are committed to pushing the boundaries of biotechnological innovation. Partnering with Femtonics Kft., we have developed a new-generation COVID test that offers unprecedented speed and mutant coverage. Our state-of-the-art test redefines the benchmark for SARS-CoV-2 detection.
Harnessing the power of personalized bioinformatics analysis, we determined a consensus sequence that covers approximately 99% of the over 2.5 million SARS-CoV-2 mutants currently catalogued in the international database. This groundbreaking approach leverages a dedicated software tool, ensuring our test’s unmatched reach when it comes to identifying COVID-19 variants.
Our team of scientists designed a set of primers specifically for viral genome detection. These primers are predicted to detect additional mutants, further enhancing the test’s ability to stay one step ahead of the evolving COVID-19 threat.
In addition to its comprehensive mutant coverage, our test offers a significant speed advantage. With a reaction time approximately 20% faster than that of regular qPCR tests and other commercially available tests based on the same principle, results can be obtained in just 4-10 minutes. This level of speed and efficiency will provide critical advantages in managing the pandemic, enabling quicker isolation of infected individuals and faster contact tracing.
Our new test maintains stringent accuracy standards, demonstrating nearly 100% specificity and 98% sensitivity. These measurements mean that the test is highly reliable in correctly identifying positive cases (sensitivity) and correctly identifying negative cases (specificity).
We have developed this reagent kit to be performed at a constant temperature of 65 °C, which simplifies the testing process, making it more accessible. Furthermore, our reagent kit offers excellent value for money compared to other PCR reagents, demonstrating our commitment to providing accessible solutions in the battle against COVID-19.
We are proud to announce that this product is CE and ISO 13485 certified, affirming its compliance with health, safety, and environmental protection standards in the European Economic Area.
The journey to develop this advanced COVID test involved a comprehensive application of our biotechnology Contract Research Organization (CRO) services. From initial concept to obtaining the CE license, we incorporated every element of our portfolio. This included personalized bioinformatics analysis, molecular cloning, and our suite of custom CRO services, underscoring the power of a multi-disciplinary approach to developing critical healthcare solutions.
